{
    "clinical_study": {
        "@rank": "9878", 
        "arm_group": [
            {
                "arm_group_label": "Augmentation", 
                "arm_group_type": "Experimental", 
                "description": "Women undergoing breast augmentation"
            }, 
            {
                "arm_group_label": "Reconstruction", 
                "arm_group_type": "Experimental", 
                "description": "Women undergoing breast reconstruction"
            }, 
            {
                "arm_group_label": "Revision-Augmentation", 
                "arm_group_type": "Experimental", 
                "description": "Women undergoing revision of previous breast augmentation"
            }, 
            {
                "arm_group_label": "Revision-Reconstruction", 
                "arm_group_type": "Experimental", 
                "description": "Women undergoing revision of previous breast reconstruction"
            }
        ], 
        "brief_summary": {
            "textblock": "Post-approval study of the safety and effectiveness of NATRELLE\u00ae 410 Highly Cohesive\n      Anatomically Shaped Silicone-Filled Breast Implants (Styles 410 FM, FF, MM, or MF) for\n      breast augmentation, reconstruction, or revision"
        }, 
        "brief_title": "NATRELLE\u00ae 410 Full and Moderate Height/Projection Breast Implant Continued Access Post-Approval Study", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Augmentation", 
            "Breast Reconstruction", 
            "Breast Implant Revision"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For entry in this study, subjects must have been enrolled in the 410 CA Clinical Study or\n        410 CARE Clinical Study under the inclusion criteria listed below and received NATRELLE\u00ae\n        410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants Styles 410 FM, FF,\n        MM, or MF in 1 (for unilateral breast reconstruction or revision) or both breasts.\n\n          -  Female, age 18 or older\n\n          -  Present with one or more of the following conditions:\n\n               -  Primary breast augmentation (i.e., no previous breast implant surgery) indicated\n                  for subject dissatisfaction, with size or shape of breast (e.g., mammary\n                  hypoplasia), asymmetry, ptosis, or aplasia\n\n               -  Primary breast reconstruction (i.e., no previous breast implant surgery other\n                  than implantation of tissue expanders or contralateral augmentation for\n                  asymmetry) indicated, in the affected breast, for mastectomy for cancer,\n                  prophylactic mastectomy, or breast trauma (resulting in mastectomy) and for the\n                  unaffected breast, contralateral asymmetry (may be performed on the date of the\n                  mastectomy or the date when permanent implants are placed in the reconstructed\n                  breast)\n\n               -  Breast implant revision surgery (i.e., removal and replacement of breast\n                  implants) indicated for previous augmentation or reconstruction with\n                  silicone-filled or saline-filled breast implants\n\n          -  Has adequate tissue available to cover implants\n\n          -  Willing to undergo MRI at the specified follow-up visit for subjects at MRI\n             designated sites and be eligible for MRI (e.g., no implanted metal or metal devices,\n             no history of severe claustrophobia)\n\n        Exclusion Criteria:\n\n        For entry in this study, subjects must have been enrolled in the 410 CA Clinical Study or\n        410 CARE Clinical Study and met the exclusion criteria listed below but not received any\n        NATRELLE\u00ae 410 Highly Cohesive Anatomically Shaped Silicone-Filled 410 X- or L-Style Breast\n        Implants\n\n          -  Does not have advanced fibrocystic disease considered to be premalignant without\n             accompanying subcutaneous mastectomy\n\n          -  Does not have existing carcinoma of the breast, without mastectomy\n\n          -  Does not have abscess or infection in the body at the time of enrollment\n\n          -  Is not pregnant or nursing\n\n          -  Does not have any disease, including uncontrolled diabetes (e.g., HbA1c > 8%), that\n             is clinically known to impact wound healing ability\n\n          -  Does not show tissue characteristics that are clinically incompatible with\n             mammaplasty, such as tissue damage resulting from radiation, inadequate tissue,\n             compromised vascularity, or ulceration\n\n          -  Does not have or is under treatment for any condition that may constitute an\n             unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems)\n\n          -  Does not show psychological characteristics that may be incompatible with the\n             surgical procedure and the prosthesis, such as inappropriate attitude or motivation\n             (e.g., body dysmorphic disorder)\n\n          -  Is not willing to undergo further surgery for revision, if medically required"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853605", 
            "org_study_id": "410CA-002"
        }, 
        "intervention": {
            "arm_group_label": [
                "Augmentation", 
                "Reconstruction", 
                "Revision-Augmentation", 
                "Revision-Reconstruction"
            ], 
            "description": "Surgical implant", 
            "intervention_name": "Anatomically shaped silicone gel-filled breast implants", 
            "intervention_type": "Device", 
            "other_name": "NATRELLE\u00ae 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Styles 410 FM, FF, MM, or MF)"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Eugene", 
                    "country": "United States", 
                    "state": "Oregon"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "overall_official": {
            "affiliation": "Allergan Medical", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The percentage of subjects and Investigators who are satisfied or definitely satisfied on a 5-point scale (definitely satisfied to definitely dissatisfied)", 
            "measure": "Subject and Investigator satisfaction", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853605"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}